^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:erlotinib (EGFR inhibitor) +
    telisotuzumab vedotin (ABBV-399) (Microtubule inhibitor, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

    Excerpt:
    ...Participant must have metastatic/locally advanced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resistant to osimertinib...
    Trial ID:
    M14-237
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

    Excerpt:
    ...50 pts received ≥1 dose of T; 8 of 23 (35%) pts on T+E were EGFR M+ and c-MET+. Rate of c-MET+ among screened NSCLC pts with adenocarcinoma and squamous (Sq) histologies was 64% and 42%, respectively….Safety profiles between T treatment schedules were comparable...Promising activity was seen for T+E in EGFR M+ and c-MET+ NSCLC...
    DOI:
    10.1093/annonc/mdy292.006
    Trial ID:
    M14-237